Upstream Bio, Inc. (UPB)
1.59
-0.41
(-20.50%)
USD |
NASDAQ |
Nov 20, 16:00
1.62
+0.03
(+1.89%)
After-Hours: 20:00
Upstream Bio Enterprise Value : -119.43M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -119.43M |
| November 19, 2026 | -96.95M |
| November 18, 2026 | -92.57M |
| November 17, 2026 | -91.47M |
| November 16, 2026 | -88.73M |
| November 13, 2026 | -54.20M |
| November 12, 2026 | -49.82M |
| November 11, 2026 | -31.18M |
| November 10, 2026 | -21.31M |
| November 09, 2026 | -10.35M |
| November 06, 2026 | -29.54M |
| November 05, 2026 | -30.63M |
| November 04, 2026 | -3.774M |
| November 03, 2026 | -20.77M |
| November 02, 2026 | -22.96M |
| October 30, 2026 | -19.67M |
| October 29, 2026 | -27.34M |
| October 28, 2026 | -43.24M |
| October 27, 2026 | -53.65M |
| October 26, 2026 | -55.84M |
| October 23, 2026 | -56.39M |
| October 22, 2026 | -42.69M |
| October 21, 2026 | -53.10M |
| October 20, 2026 | -52.01M |
| October 19, 2026 | -53.10M |
| Date | Value |
|---|---|
| October 16, 2026 | -55.30M |
| October 15, 2026 | -21.86M |
| October 14, 2026 | -19.12M |
| October 13, 2026 | -12.00M |
| October 12, 2026 | 21.99M |
| October 09, 2026 | 51.04M |
| October 08, 2026 | 42.82M |
| October 07, 2026 | 46.10M |
| October 06, 2026 | 45.01M |
| October 05, 2026 | 59.26M |
| October 02, 2026 | 69.67M |
| October 01, 2026 | 69.67M |
| September 30, 2026 | 82.28M |
| September 29, 2026 | 23.91M |
| September 28, 2026 | 29.93M |
| September 25, 2026 | 33.22M |
| September 24, 2026 | 22.81M |
| September 23, 2026 | 23.91M |
| September 22, 2026 | 40.34M |
| September 21, 2026 | 33.49M |
| September 18, 2026 | 32.12M |
| September 17, 2026 | 30.48M |
| September 16, 2026 | 31.58M |
| September 15, 2026 | 39.79M |
| September 14, 2026 | 57.87M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.19M |
| Revenue (Quarterly) | 0.395M |
| Total Expenses (Quarterly) | 41.59M |
| EPS Diluted (Quarterly) | -0.7519 |
| Gross Profit Margin (Quarterly) | 87.59% |
| Profit Margin (Quarterly) | -10.43K% |
| Earnings Yield | -189.5% |
| Normalized Earnings Yield | -189.27 |